Can Ipilimumab restore immune response in advanced NSCLC after progression on anti‐PD‐1/PD‐L1 agents?

Anti‐PD‐1/PD‐L1 agents play a crucial part in the treatment of non‐small cell cancer (NSCLC) demonstrating improved overall response rate (ORR) and overall survival (OS). Recent studies evaluating combination treatment with anti‐PD‐1 and anti‐CTLA‐4 suggests improved outcome but also increased toxic...

Descripción completa

Detalles Bibliográficos
Autores principales: Sternschuss, Michal, Peled, Nir, Allen, Aaron M., Dudnik, Elizabeth, Rotem, Ofer, Kurman, Noga, Gal, Omer, Reches, Hiba, Zer, Alona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2020
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7396365/
https://www.ncbi.nlm.nih.gov/pubmed/32548905
http://dx.doi.org/10.1111/1759-7714.13502

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7396365/
https://www.ncbi.nlm.nih.gov/pubmed/32548905
http://dx.doi.org/10.1111/1759-7714.13502

Ejemplares similares